<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03785015</url>
  </required_header>
  <id_info>
    <org_study_id>ReASA</org_study_id>
    <nct_id>NCT03785015</nct_id>
  </id_info>
  <brief_title>When Should Low-dose Aspirin be Resumed After Peptic Ulcer Bleeding?</brief_title>
  <official_title>When Should Low-dose Aspirin be Resumed After Peptic Ulcer Bleeding? A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute upper gastrointestinal (GI) bleeding associated with the use of low-dose aspirin (ASA)&#xD;
      is a major cause of peptic ulcer bleeding worldwide. Among survivors of acute myocardial&#xD;
      infarction, a study of over 14,000 patients reported that the risk of life-threatening GI&#xD;
      bleeding in the first two months is 7 times higher than that in the subsequent months. After&#xD;
      endoscopic control of ulcer bleeding, most patients with cardiovascular (CV) diseases will&#xD;
      need to resume ASA. However, the investigator found that immediate resumption of ASA saves&#xD;
      life but at the expense of higher risk of recurrent bleeding. Peptic ulcer bleeding&#xD;
      associated with ASA is a major cause of hospitalization in Hong Kong. Currently, ASA use has&#xD;
      contributed to about one-third of the bleeding ulcers admitted to our hospital that serves a&#xD;
      local population of 1.5 million. Accordingly, current international guidelines recommend&#xD;
      early resumption of ASA but the optimal timing is unknown. Clinicians often face the dilemma:&#xD;
      when should ASA be resumed? Furthermore, patients who suffer from acute peptic ulcer bleeding&#xD;
      are often elderly patients with significant co-morbidities. Mortality in these patients&#xD;
      remains high. Clinicians are facing an increasing number of patients who are on antiplatelet&#xD;
      drugs or anticoagulants. The investigator proposes a open-label randomized-controlled trial&#xD;
      to evaluate the optimal timing of resuming ASA in patients with CV diseases complicated by&#xD;
      peptic ulcer bleeding. Patients will be randomized to resume the standard treatment within&#xD;
      first few hours or only to resume the standard treatment 72 hours after endoscopic&#xD;
      haemostasis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute upper gastrointestinal (GI) bleeding associated with the use of low-dose aspirin (ASA)&#xD;
      is a major cause of peptic ulcer bleeding worldwide. Among survivors of acute myocardial&#xD;
      infarction, a study of over 14,000 patients reported that the risk of life-threatening GI&#xD;
      bleeding in the first two months is 7 times higher than that in the subsequent months (1).&#xD;
      After endoscopic control of ulcer bleeding, most patients with cardiovascular (CV) diseases&#xD;
      will need to resume ASA. Clinicians often face the dilemma: when should ASA be resumed?&#xD;
      Furthermore, patients who suffer from acute peptic ulcer bleeding are often elderly patients&#xD;
      with significant co-morbidities. Mortality in these patients remains high. Clinicians are&#xD;
      facing an increasing number of patients who are on antiplatelet drugs or anticoagulants.&#xD;
&#xD;
      However, there are very limited data to guide the best timing for resumption of ASA in these&#xD;
      high risk patients. To date, our group has conducted the only randomized controlled trial in&#xD;
      the literature that has partially addressed this issue. Importantly, the investigator found&#xD;
      that immediate resumption of ASA saves life but at the expense of higher risk of recurrent&#xD;
      bleeding (2). Accordingly, current international guidelines recommend early resumption of ASA&#xD;
      but the optimal timing is unknown.&#xD;
&#xD;
      In the setting of acute GI bleeding, it is often a dilemma whether to stop or to restart&#xD;
      these drugs. The balance between bleeding and thrombotic risks is difficult and treatment is&#xD;
      often empirical and not evidence-based.&#xD;
&#xD;
      The investigator aims to test the hypothesis that in ASA users complicated by peptic ulcer&#xD;
      bleeding, withholding ASA till day 3 reduces the risk of recurrent bleeding compared to&#xD;
      immediate resumption of ASA without a significant increase in mortality.&#xD;
&#xD;
      References&#xD;
&#xD;
        1. Moukarbel GV, Signorovitch JE, Pfeffer MA et al. Gastrointestinal bleeding in high risk&#xD;
           survivors of myocardial infarction: the VALIANT Trial. Eur Heart J 2009;30(18):2226-32.&#xD;
&#xD;
        2. Sung JJ, Lau JY, Ching JY et al. Continuation of low-dose aspirin therapy in peptic&#xD;
           ulcer bleeding: a randomized trial. Ann Intern Med 2010;152(1):1-9.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 14, 2019</start_date>
  <completion_date type="Anticipated">February 28, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrent peptic ulcer bleeding</measure>
    <time_frame>30 days after endoscopic treatment</time_frame>
    <description>Recurrent peptic ulcer bleeding within 30 days of endoscopic treatment</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">436</enrollment>
  <condition>Aspirin</condition>
  <condition>GastroIntestinal Bleeding</condition>
  <arm_group>
    <arm_group_label>Withold aspirin till after endoscopic haemostasis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Withhold the standard treatment of aspirin within 12 hours after endoscopic haemostasis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Withold aspirin till 72 hours</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Withhold the standard treatment of aspirin till 72 after endoscopic haemostasis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Resume Aspirin within 12 hours</intervention_name>
    <description>Resume the standard treatment within 12 hours after endoscopic haemostasis</description>
    <arm_group_label>Withold aspirin till after endoscopic haemostasis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Resume Aspirin 72 - 84 hours</intervention_name>
    <description>Resume the standard treatment between 72 and 84 hours after endoscopic haemostasis</description>
    <arm_group_label>Withold aspirin till 72 hours</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt;18&#xD;
&#xD;
          2. Patients with actively bleeding gastroduodenal lesions (peptic ulcer, bleeding&#xD;
             erosions, or Dieulafoy's lesion) or ulcers showing other high risk stigmata (visible&#xD;
             blood vessels or adherent clots) treated by endoscopic therapy&#xD;
&#xD;
          3. Subjects continue to require regular ASA or dual anti-platelet therapy for treatment&#xD;
             of CV or cerebrovascular diseases after this bleeding episode&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who received ASA for primary prophylaxis&#xD;
&#xD;
          2. Unsuccessful endoscopic hemostasis of bleeding ulcers or ulcer perforation&#xD;
&#xD;
          3. Gastric outlet obstruction&#xD;
&#xD;
          4. Known sensitivity to PPIs&#xD;
&#xD;
          5. Previous partial gastrectomy or vagotomy&#xD;
&#xD;
          6. Patients need concomitant anticoagulant&#xD;
&#xD;
          7. Pregnant unless sterilization, menopause or last menstrual period within 7 days&#xD;
&#xD;
          8. Other co-morbidities or advanced age that will hinder the drug compliance or follow up&#xD;
&#xD;
          9. Malignancy on active treatment&#xD;
&#xD;
         10. Unable to give consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Siew C Ng, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese University of Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ka Man Kee, MPH</last_name>
    <phone>85235053855</phone>
    <email>carmenkee@cuhk.edu.hk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jessica Ching, MPH</last_name>
    <phone>85235053524</phone>
    <email>jessicaching@cuhk.edu.hk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Siew Chien Ng, PhD</last_name>
      <phone>35053996</phone>
      <email>siewchienng@cuhk.edu.hk</email>
    </contact>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>December 20, 2018</study_first_submitted>
  <study_first_submitted_qc>December 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2018</study_first_posted>
  <last_update_submitted>October 20, 2020</last_update_submitted>
  <last_update_submitted_qc>October 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Siew Chien NG</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Hemorrhage</mesh_term>
    <mesh_term>Peptic Ulcer</mesh_term>
    <mesh_term>Peptic Ulcer Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

